Ranolazine-d5

Ranolazine-d5

• CAS Number: 1092804-87-9
• UNSPSC Description: Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
• Target Antigen: Calcium Channel; Isotope-Labeled Compounds; Sodium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling;Others
• Field of Research: Cardiovascular Disease; Cancer
• Solubility: 10 mM in DMSO
• Smiles: CC(C=CC=C1C)=C1NC(CN(CC2)CCN2C([2H])([2H])C(O)([2H])C([2H])([2H])OC3=C(C=CC=C3)OC)=O
• Molecular Weight: 432.57
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.|[3]Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.|[4]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported